Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.

@article{Arns2005EntericcoatedMS,
  title={Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.},
  author={Wolfgang Arns and Stephan Breuer and Somesh Choudhury and Guy Taccard and James H F Lee and Vera Binder and J{\"u}rgen Roettele and Robert L. Schmouder},
  journal={Clinical transplantation},
  year={2005},
  volume={19 2},
  pages={199-206}
}
Mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF), is routinely used as an adjunct immunosuppressant therapy in renal transplantation. Although highly effective, MMF therapy is associated with significant gastrointestinal adverse effects. Enteric-coated mycophenolate sodium (EC-MPS) is an advanced formulation delivering MPA. The enteric coat dissolves at pH > 5 allowing for MPA delivery in the small intestine. A single-center, open-label, randomized, three-way crossover… CONTINUE READING